ZSET-845 is a cognitive enhancer which enhances choline acetyltransferase activity in the hippocampus in the rat.
ZSET-845 has no inhibitory action on AChE activity and enhances choline acetyltransferase (ChAT) activity in NB-1 cells[1].
Treatment with ZSET-845 at the dose of 0.01, 0.1 and 1 mg/kg significantly ameliorates impaired performance caused by scopolamine. Oral administration of ZSET-845 causes an increase in ChAT activity in the hippocampus. In the hippocampus, ZSET-845 (0.01, 0.1 or 1 mg/kg) significantly increases ChAT activity (112%, 113.8% or 108.7%, respectively) compared with matched vehicle-injected control rats[1]. Oral administration of ZSET845 at a dose of 1 or 10 mg/kg ameliorates learning impairment in passive avoidance task and enhanced ChAT activity in the basal forebrain, medial septum and hippocampus, and increases in the number of ChAT-immunoreactive cells in the medial septum in Ab-treated rats to the levels of vehicle-injected control rats[2].
[1]. Yamaguchi Y, et al. Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat. Jpn J Pharmacol. 2001 Nov;87(3):240-4. [2]. Yamaguchi Y, et al. Antiamnesic effects of azaindolizinone derivative ZSET845 on impaired learning and decreased ChAT activity induced by amyloid-beta 25-35 in the rat. Brain Res. 2002 Aug 2;945(2):259-65.